Scenario 3: A 44-Year-Old Woman With RCC at Intermediate-High Risk for Recurrence

Expert panelists highlight aspects of a final patient scenario, discussing adjuvant treatment strategies in the setting of renal cell carcinoma at intermediate-high risk for recurrence.

Related Keywords

,Optimizing Outcomes ,Patients With ,Translating Evidence ,Clinical Practice ,Year Old Woman With ,Intermediate High Risk ,Renal Cell Carcinoma ,Nrcc ,Kidney Cancer ,Pembrolizumab ,Adjuvant Pembrolizumab ,Trio Therapy ,Immune Checkpoint Inhibitors ,Keynote 564 ,Prosper Trial ,Prosper Study ,Immotion010 ,Atezolizumab ,Nivolumab ,Ipilimumab ,Combination Therapy ,Novel Therapy ,Risk Of Recurrence ,Risk For Recurrence ,Recurrence Risk ,